A Phase 4 interventional study of Hypertonic saline and 0.9% saline in Cardiovascular Diseases and Valvular Heart Disease, sponsored by Insel Gruppe AG, University Hospital Bern. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-24.
Sponsored by Insel Gruppe AG, University Hospital Bern · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Heart Valve Diseases with a site in Switzerland — 8 open to participants now, 12 under way, none of them phase 3. Heart Valve Diseases · Switzerland.
Among the 31 studies in Heart Valve Diseases with a site in Switzerland, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 4, and was the 14th registered.
556 studies on the registry are indexed under Heart Valve Diseases; 166 are open to participants now.
Browse Heart Valve Diseases studies →8 of the 31 studies in Heart Valve Diseases with a site in Switzerland are open now. Recruiting first, the newest first:
Edwards Lifesciences · Sites in Switzerland, Germany, Greece and 3 more countries
Montefiore Medical Center · Sites in Switzerland, United States, Canada and 5 more countries
Ages 18+
Corcym S.r.l · Sites in Switzerland, United States, Austria and 10 more countries
Erasmus Medical Center · Sites in Switzerland, United States, Austria and 9 more countries
Ages 18+
NeoChord · Sites in Switzerland, Germany, Greece
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2 · Phase 4 2
First in 2006; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 100 across 314 interventional studies indexed under Heart Valve Diseases.
Median enrollment 173 across the 19 interventional studies, 239 across the 12 observational. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 31 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 742 studies on the registry; 180 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 2 studies filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Heart Valve Diseases with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Heart Valve Diseases with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Volume replacement strategies and type of fluid used in patients undergoing cardiac surgery have changed during the last years. Currently used crystalloid solutes have a variable composition and a major impact on organ function and outcome. Additionally critically ill patients are prone to fluid overload, which is despite common perception, not a benign occurrence as it is associated with prolonged ICU- and hospital length of stay and increased mortality rates. Fluid resuscitation using bolus or continuous infusion of hypertonic saline was used for more than thirty years. Only a few studies have been conducted so far, but they showed that infusion of hypertonic saline results in less volume administered, increased renal function less weight gain in critically ill patients when compared to other crystalloids.
Aim: This preliminary randomized controlled double-blind study aims to identify whether fluid resuscitation using hypertonic saline (HS) when used in addition to lactated Ringers solution results in less total fluid amount administered in patients following cardiac surgery. Additionally we want to evaluate whether the use of hypertonic saline results less need for pharmacological cardiocirculatory support, increased renal function, less postoperative volume overload shortened post-cardiac bypass immune suppression and increased postoperative outcomes.
Study intervention: At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl or 0.9% NaCl by infusion pump over 60 minutes. If necessary, fluid resuscitation will thereafter be performed with Ringer's lactate to normalize peripheral perfusion and to allow weaning of vasopressors.
556 studies on the registry are indexed under Heart Valve Diseases; 166 are open to participants now.
This study's enrollment of 165 is above the median of 100 across 314 interventional studies indexed under Heart Valve Diseases.
Browse Heart Valve Diseases studies →Insel Gruppe AG, University Hospital Bern is the lead sponsor of 742 studies on the registry; 180 are open to participants now.
Compared within Heart Valve Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
Drug: Hypertonic saline
At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
Drug: 0.9% saline
At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
Also known as: 7.9% NaCl
At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
Also known as: normal saline
total cumulative amount of fluids infused
Time frame: daily until ICU discharge, max until postoperative day 90
postoperative weight gain
Time frame: until postoperative day 6
total postoperative cumulative urinary output
Time frame: daily until ICU discharge, max until postoperative day 90
total cumulative dose of inopressors per kg bodyweight /hour
cumulation of norepinephrine and epinephrine
Time frame: until ICU discharge, max until postoperative day 90
time on inopressors
norepinephrine and/or epinephrine
Time frame: from ICU admission until stop of inopressors, max until postoperative day 90
variation in renal function markers
renal damage maker (TIMP2-IGFB, creatinine)
Time frame: until postoperative day 6
variation in acid-base homeostasis
pH, base excess, lactate, bicarbonate, electrolytes
Time frame: until postoperative day 6
variation in immune function
mHLA-DR
Time frame: until postoperative day 6
time on the ventilator
Time frame: from ICU admission until time of extubation, maximum 90 days
occurence of infection
Time frame: occurence of infection during the index hospitalisation or subsequent admissions due to infection upto 90 postoperative days
length of stay
time to ICU/hospital-discharge
Time frame: time to ICU/hospital-discharge however long this may take, maximum 90 days
readmissions to the ICU
Time frame: readmissions to the ICU within postoperative 90 days
mortality
Time frame: until postoperative day 90
Plan to share: No
Ran from Feb 2018 to primary completion in May 2019, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →